Caelus Health

Foundation date

11-1-2017

Sector

#Biotechnology - Therapeutics

Therapeutic areas

Caelus Health is a biotech company developing an entirely new class of Microbiome Therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes (T2DM) in people with metabolic syndrome.The company is dedicated to the commercialisation of functional food and pharmabiotic products for the prevention and early treatment of cardio metabolic diseases – based on the strong correlation between the intestinal microbiome and health.  

Upcoming events

Latest news

  • SeptiCyte® RAPID receives 510(k) clearance by US FDA

    Wednesday December 1st 2021

  • QbD and Inovigate launch Health to Market, a contract commercialization organization in life sciences

    Wednesday December 1st 2021

  • Dimitrios Mantzilas joins Precirix as Chief Technology Officer

    Wednesday December 1st 2021